Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Doxil, Melphalan, and Velcade in Relapsed/Refractory Multiple Myeloma
NCT00334932Phase 2Unknown
- Sponsor
- Herbert Irving Comprehensive Cancer Center
- Start
- Feb 2006
- Primary completion
- Jan 2010
- Modality
- Modified Peptides, Targeted Liposomes, Stealth (PEGylated) Liposomes
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib, melphalan, pegylated liposomal doxorubicin in multiple myeloma (MM), sponsored by Herbert Irving Comprehensive Cancer Center. Status: unknown.
02
Drugs
bortezomibmelphalanpegylated liposomal doxorubicin
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00334932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00334932.